Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Glucose monitor could spot diabetes risk after pregnancy

NCT ID NCT07034261

Knowledge-focused Sponsor: University of Chicago Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study will test whether a continuous glucose monitor (CGM) worn for 14 days after childbirth can predict which women with a history of gestational diabetes are at risk for developing type 2 diabetes. Fifty participants will wear a blinded CGM device and then take a standard oral glucose tolerance test 4-12 weeks after delivery. The goal is to see if the CGM data can replace or improve upon the standard test for detecting postpartum blood sugar problems.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Blinded Continuous Glucose Monitoring Device
What this could lead to
If successful, this could show that a simple 14-day glucose monitor can identify women at risk for type 2 diabetes after gestational diabetes, potentially leading to earlier detection and prevention.
What could go wrong
This is a small, early-stage study (50 participants) that is not yet recruiting. It only measures how well the monitor predicts results of a standard test, not whether it improves health outcomes. The device is blinded, so participants cannot see their own glucose levels during the study.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 50 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Sep 2026

An estimate. Start dates often move.

Expected to finish

Sep 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Age greater than or equal to 18 2. Completed pregnancy with delivery of a live born infant(s). Pregnancies with multiple gestations will be included 3. No prior history of type 1 or type 2 diabetes \* Patients with a history of gestational diabetes (GDM) in a prior pregnancy will be eligible for inclusion. 4. GDM diagnosis by standard screening at 24-28 weeks * 2 hour 75g oral glucose tolerance test (OGTT); one abnormal value required for diagnosis * Fasting glucose 92 * 1 hour 180 * 2 hour 153 * 3 hour 100g OGTT - two abnormal values required for diagnosis * Fasting glucose - 95 * 1 hour 180 * 2 hour 155 * 3 hour 140 There are no exclusion criteria for this study. Eligibility will be based on inclusion criteria.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Gestational diabetes are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

gestational diabetes

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Gestational diabetes

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.